Rationales behind the choice of administration form with fentanyl: Delphi survey among Danish general practitioners

Journal of Opioid Management

Volumn 6, Issue 4, 2010, Pages 259-268

  Jacobsen, Ramune ^a   Møldrup, Claus ^b   Christrup, Lona ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Administration; Fentanyl; General practitioners; Rationale

Indexed keywords

FENTANYL; NOSE SPRAY; AEROSOL; NARCOTIC ANALGESIC AGENT;

ANALGESIA; ARTICLE; BRAINSTORMING; DELPHI STUDY; DENMARK; DRUG ADMINISTRATION; DRUG COST; DRUG HYPERSENSITIVITY; DRUG SELF ADMINISTRATION; GENERAL PRACTITIONER; INJECTION; INTERNET; PAIN; PRESCRIPTION; TERMINALLY ILL PATIENT; XEROSTOMIA; AEROSOL; ATTITUDE TO HEALTH; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; DECISION MAKING; ECONOMICS; GENERAL PRACTICE; HEALTH CARE SURVEY; HEALTH PERSONNEL ATTITUDE; HUMAN; INTRADERMAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; TERMINAL CARE;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; AEROSOLS; ANALGESICS, OPIOID; ATTITUDE OF HEALTH PERSONNEL; CHOICE BEHAVIOR; COST-BENEFIT ANALYSIS; DELPHI TECHNIQUE; DENMARK; DRUG COSTS; FAMILY PRACTICE; FENTANYL; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PAIN; PHYSICIAN'S PRACTICE PATTERNS; TERMINAL CARE; PRACTICE PATTERNS, PHYSICIANS';

EID: 77957302925     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2010.0024     Document Type: Article

References (41)

1. Zacny JP, Lichtor JL, Zaragoza JG, et al.: Subjective and behavioral responses to intravenous fentanyl in healthy volunteers. Psychopharmacology (Berl). 1992; 107: 319-326.
2. Jeal W, Benfield P: Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs. 1997; 53: 109-138.
3. Fine PG, Streisand JB: A review of oral transmucosal fentanyl citrate: Potent, rapid and noninvasive opioid analgesia. J Palliat Med. 1998; 1: 55-63.
4. Danish Medicine Agency (Laegemiddelstyrelsen): The list of approved medicines. Available at http://www.laegemiddelstyrelsendk/. Accessed December 19, 2007.
5. Slatkin NE, Xie F, Messina J, et al.: Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol. 2007; 5: 327-334.
6. U.S. Food and Drug Administration: Duragesic Label. Available at http://www.fda.gov/cder/fol/label/2005/19813s0391b1pdf. Accessed December 19, 2007.
7. U.S. Food and Drug Administration: Medication Guide Actiq. Available at http://www.fda.gov/cder/Offices/ODS/MG/fentanyl-citrateMGpdf. Accessed December 20, 2007.
8. Mosser KH: Transdermal fentanyl in cancer pain. Am Fam Physician. 1992; 45: 2289-2294.
9. Southam MA: Transdermal fentanyl therapy: System design, pharmacokinetics and efficacy. Anticancer Drugs. 1995; 6: 29-34.
10. Mystakidou K, Katsouda E, Tsilika E, et al.: Transdermal therapeutic fentanyl-system (TTS-F). In Vivo. 2004; 18: 633-642.
11. Gourlay GK: Treatment of cancer pain with transdermal fentanyl. Lancet Oncol. 2001; 2: 165-172. (Pubitemid 33585928)
12. Kornick CA, Santiago-Palma J, Moryl N, et al.: Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf. 2003; 26: 951-973.
13. Mercadante S, Fulfaro F: Alternatives to oral opioids for cancer pain. Oncology (Williston Park). 1999; 13: 215-225.
14. Radovanovic D, Pjevic M, Malbasa Z, et al.: The use of transdermal fentanyl in the treatment of cancer pain. Arch Oncol. 2002; 10: 263-266. (Pubitemid 36164139)
15. Simmonds MA, Richenbacher J: Transdermal fentanyl: Long-term analgesic studies. J Pain Symptom Manage. 1992; 7: S36-S39.
16. Gordon DB: Oral transmucosal fentanyl citrate for cancer breakthrough pain: A review. Oncol Nurs Forum. 2006; 33: 257-264.
17. Mystakidou K, Katsouda E, Parpa E, et al.: Oral transmucosal fentanyl citrate: Overview of pharmacological and clinical characteristics. Drug Deliv. 2006; 13: 269-276.
18. Rees E: The role of oral transmucosal fetanyl citrate in the management of breakthrough cancer pain. Int J Palliat Nurs. 2002; 8: 304-308.
19. Zeppetella G, Ribeiro MD: Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev. 2006; 25: CD0043H.
20. Reddy SK, Nguyen P: Breakthrough pain in cancer patients: New therapeutic approaches to an old challenge. Curr Rev Pain. 2000; 4: 242-247.
21. Christrup LL, Foster D, Popper LD, et al.: Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: A randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther. 2008; 30: 469-481. (Pubitemid 351483922)
22. Foster D, Upton R, Christrup L, et al.: Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann Pharmacother. 2008; 42: 1380-1387.
23. Zeppetella G: An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: A pilot study. J Pain Symptom Manage. 2000; 20: 253-258.
24. Efstathiou N, Ameen J, Coll AM: Healthcare providers' priorities for cancer care: A Delphi study in Greece. Eur J Oncol Nurs. 2007; 11: 141-150.
25. Moldrup C, Morgall JM: Risks of future drugs: A Danish expert Delphi. Technol Forecast Soc Change. 2001; 67: 273-289.
26. Stevens B, McGrath P, Yamada J, et al.: Identification of pain indicators for infants at risk for neurological impairment: A Delphi consensus study. BMC Pediatr. 2006; 6: 1.
27. Akins RB, Toison H, Cole BR: Stability of response characteristics of a Delphi panel: Application of bootstrap data expansion. BMC Med Res Methodol. 2005; 5: 37.
28. Nevo D, Chan YE: A Delphi study of knowledge management systems: Scope and requirements. Inf Manage. 2007; 44: 538-597.
29. Campbell SM, Cantrill JA, Roberts D: Prescribing indicators for UK general practice: Delphi consultation study. BMJ. 2000; 321: 425-428.
30. Rasmussen HM, Sondergaard J, Kampmann JP, et al.: General practitioners prefer prescribing indicators based on detailed information on individual patients: A Delphi study. Eur J Clin Pharmacol. 2005; 61: 237-241. (Pubitemid 40768558)
31. Fayers PM, Machin D: Quality of Life. Assessment, Analysis and Interpretation. Chichester, England: Wiley, 2007.
32. Kilner T: Educating the ambulance technician, paramedic, and clinical supervisor: Using factor analysis to inform the curriculum. Emerg Med J. 2004; 21: 379-385.
33. John Bell & Associates: Statistics for practical people. Available at http://www.proaxis.com/~johnbell/sfpp/sfpp6.htm. Accessed January 28, 2008.
34. Bland JM, Altman DG: Cronbach's alpha. Br Med J. 1997; 314: 572.
35. DeVellis RF: Scale Development: Theory and Applications. Thousand Oaks, CA: Sage Publications, 2003.
36. Mystakidou K, Katsouda E, Parpa E, et al.: Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: An overview of its pharmacological and clinical characteristics. Am J Hospice Palliat Care. 2005; 22: 228-232.
37. Dale O, Hjortkjaer R, Kharasch ED: Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand. 2002; 46: 759-770.
38. Baker JA, Lovell K, Harris N, et al.: Multidisciplinary consensus of best practice for pro re nata (PRN) psychotropic medications within acute mental health settings: A Delphi study. J Psychiatr Mental Health Nurs. 2007; 14: 478-484.
39. Richter A, Ostrowski C, Dombeck MP, et al.: Delphi panel study of current hypertension treatment patterns. Clin Ther. 2001; 23: 160-167. (Pubitemid 32114171)
40. Powell C: The Delphi technique: Myths and realities. J Adv Nurs. 2003; 41: 376-382.
41. Sackman H: Delphi Critique. Expert Opinion, Forecasting, and Group Process. Lexington: Lexington Books, 1975.